| 000 | 01129 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250514023230.0 | ||
| 264 | 0 | _c20020418 | |
| 008 | 200204s 0 0 ger d | ||
| 022 | _a0340-1855 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchattenkirchner, M | |
| 245 | 0 | 0 |
_a[New basic therapeutic drugs from the viewpoint of evidence-based therapy]. _h[electronic resource] |
| 260 |
_bZeitschrift fur Rheumatologie _cDec 2001 |
||
| 300 |
_a473-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadverse effects |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 |
_aIsoxazoles _xadverse effects |
| 650 | 0 | 4 | _aLeflunomide |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tZeitschrift fur Rheumatologie _gvol. 60 _gno. 6 _gp. 473-6 |
|
| 999 |
_c11736273 _d11736273 |
||